Blueshift Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Blueshift Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$694K	Buy	2,834 +1,038	+58%	+$225K	0.16%	129
2026 Q1	$304K	Buy	+1,796	New	+$310K	0.09%	340
2023 Q2	–	Sell	-3,763	Closed	-$232K	–	340
2023 Q1	$232K	Buy	+3,763	New	+$247K	0.1%	272
2022 Q4	–	Sell	-4,834	Closed	-$216K	–	357
2022 Q3	$216K	Buy	+4,834	New	+$242K	0.05%	492
2019 Q3	–	Sell	-31,544	Closed	-$812K	–	723
2019 Q2	$812K	Buy	+31,544	New	+$632K	0.11%	291

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Blueshift Asset Management's AXSM Position: Q2 2026 in Review

Blueshift Asset Management increased its Axsome Therapeutics (AXSM) stake by 58% in Q2 2026, buying an estimated $225K and bringing the position to 2,834 shares worth $694K. The position accounts for 0.16% of the portfolio, ranked #129.

Blueshift Asset Management first reported a position in AXSM in Q2 2019 and has held it in 5 quarters since. The position peaked at $812K in Q2 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Blueshift Asset Management held 2,834 shares of Axsome Therapeutics worth $694K as of Q2 2026.
Blueshift Asset Management bought 1,038 Axsome Therapeutics shares in Q2 2026, an estimated $225K.
Axsome Therapeutics made up 0.16% of Blueshift Asset Management's portfolio in Q2 2026, its #129 holding.
Blueshift Asset Management first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 5 quarters since.
Blueshift Asset Management's Axsome Therapeutics position peaked at $812K in Q2 2019.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Blueshift Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.